{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T18:25:57Z","timestamp":1789928757988,"version":"4.0.1"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1097\/fpc.0000000000000278","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T23:20:13Z","timestamp":1491434413000},"page":"223-226","source":"Crossref","is-referenced-by-count":8,"title":["Influence of CYP2C8 polymorphisms on imatinib steady-state trough level in chronic myeloid leukemia and gastrointestinal stromal tumor patients"],"prefix":"10.1097","volume":"27","author":[{"given":"Michiel C.","family":"Verboom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loes","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sander","family":"Kouwen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse J.","family":"Swen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Diepstraten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ward F.","family":"Posthuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dani\u00eblle","family":"van Lammeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik B.","family":"Wilms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210213","doi-asserted-by":"crossref","first-page":"vii72","DOI":"10.1093\/annonc\/mds228","article-title":"Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"23","author":"Baccarani","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl 3","key":"R2-2-20210213","first-page":"iii21","article-title":"Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"25","year":"2014","journal-title":"Ann Oncol"},{"key":"R3-2-20210213","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/FTD.0b013e31823cdec9","article-title":"The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors","volume":"34","author":"Teng","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R4-2-20210213","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2008.20.4818","article-title":"Imatinib plasma levels are correlated with clinical benefit in patients with unresectable\/metastatic gastrointestinal stromal tumors","volume":"27","author":"Demetri","year":"2009","journal-title":"J Clin Oncol"},{"key":"R5-2-20210213","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1124\/dmd.112.048017","article-title":"Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response","volume":"41","author":"Filppula","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"R6-2-20210213","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/00498254.2015.1060649","article-title":"Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib","volume":"46","author":"Khan","year":"2016","journal-title":"Xenobiotica"},{"key":"R7-2-20210213","doi-asserted-by":"crossref","first-page":"467","DOI":"10.3109\/00498254.2010.487163","article-title":"Functional characterization of five CYP2C8 variants and prediction of CYP2C8 genotype-dependent effects on in vitro and in vivo drug-drug interactions","volume":"40","author":"Gao","year":"2010","journal-title":"Xenobiotica"},{"key":"R8-2-20210213","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/FTD.0000000000000004","article-title":"Plasma concentrations of tyrosine kinase inhibitors imatinib, erlotinib, and sunitinib in routine clinical outpatient cancer care","volume":"36","author":"Lankheet","year":"2014","journal-title":"Ther Drug Monit"},{"key":"R9-2-20210213","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin Cancer Res"},{"key":"R10-2-20210213","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/annonc\/mds532","article-title":"Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients","volume":"24","author":"Seong","year":"2013","journal-title":"Ann Oncol"},{"key":"R11-2-20210213","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1182\/blood-2007-10-116475","article-title":"Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study","volume":"111","author":"Larson","year":"2008","journal-title":"Blood"}],"container-title":["Pharmacogenetics and Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FPC.0000000000000278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:23:50Z","timestamp":1620951830000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01213011-201706000-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":11,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/fpc.0000000000000278","relation":{},"ISSN":["1744-6872"],"issn-type":[{"value":"1744-6872","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]}}}